Clinical Trial

A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment

Name: A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment — clinical trial record (NCT06987500)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to characterize the safety, tolerability, and efficacy of XNW29016 in participants with advanced solid tumors .

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-05-22.

Trial Details

NCT Number	NCT06987500
Lead Sponsor	Evopoint Biosciences Inc. Collaborators: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions	Tumor, Solid
Enrollment	132 participants
Start Date	2025-04-11
Primary Completion	2027-02-14 (estimated)
Study Completion	2027-08-16 (estimated)
Updated on ClinicalTrials.gov	2025-06-06